Appendix 1. Guidelines and Measure-Specific Testing Results

Use of Higher-than-Recommended Doses of Antipsychotics in Children and Adolescents

Guidelines Regarding Use of Higher-than-Recommended Doses of Antipsychotics in Children and Adolescents

Organization (Year)	Care Setting	Relevant Population	Recommendation	Grade*
American Academy of	Not specified	Children and	AACAP Practice Parameters for the Use of Atypical Antipsychotic Medications in	Clinical Guidelines (based
Child and Adolescent		adolescents		on strong empirical
Psychiatry (2011)			"Dosing of AAAs [atypical antipsychotics] should follow the 'start low and go slow'	evidence and/or strong
			approach and seek to find the lowest effective dose."	clinical consensus)
American Academy of	Not specified	Children and	Practice Parameter for the Assessment and Treatment of Children and	Not specified
Child and Adolescent		adolescents	Adolescents with Schizophrenia: " medication dosage should be periodically	
Psychiatry (2001)			reassessed to ensure that the lowest effective dose is being used."	
TX Dept. of Family	Foster care	Children (no age	Psychotropic Medication Utilization Parameters for Foster Children	Expert consensus
and Protective		specified)	"Psychotropic medication dose exceeds usual recommended doses" is a situation	
Services (2010)			that "suggests the need for additional review of a patient's clinical status," and	
			specifies recommended doses.	

^{*}Guideline Organization's assessment of evidence specified in guideline

References

Texas Department of Family and Protective Services and the University of Texas at Austin College of Pharmacy. Psychotropic Medication Utilization Parameters for Foster Children. December 2010. http://www.dfps.state.tx.us/documents/Child Protection/pdf/TxFosterCareParameters-December2010.pdf

American Academy of Child and Adolescent Psychiatry. Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines. Journal of the American Academy of Child & Adolescent Psychiatry. December 2007. Vol46 (12):1532-1572. http://www.jaacap.com/article/S0890-8567(09)61867-0/abstract

American Academy of Child and Adolescent Psychiatry. Prescribing Psychoactive Medication for Children and Adolescents. 2001.

http://www.aacap.org/AACAP/Policy Statements/2001/Prescribing Psychoactive Medication for Children and Adolescents.aspx

Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) AHRQ Publication No. 11-EHC087-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2011.

Physician Desk Reference. 64th Edition. 2010. Montvale, NJ: PDR Network LLC.

Martin A, Lawrence Scahill L, Charney D, and Leckman J. (Ed.) Pediatric Psychopharmacology: Principles and Practice. 2010. New York: Oxford University Press.

Measure-Specific Testing Results

Table 1. Proportion of Children on Higher-than-Recommended Doses of Antipsychotics by Race/Ethnicity: General and Foster Care Population

RACE/ETHNICITY	General Population (%)	Foster Care Population (%)	
White Non-Hispanic	7.9	10.3	
Black Non-Hispanic	8.5	11.1	
Hispanic	7.2	9.1	
Other	7.7	10.6	
Unknown	11.5	9.8	

Table 2. Average State Performance by Population

	General Population (%)	Foster Care Population (%)
Percentage of children who receive at least two antipsychotic	7.0	9.2
prescriptions with higher-than-recommended doses	1.3	9.2

Table 3. Proportion of Children on Higher-than-Recommended Doses of Antipsychotics by Rurality/Urbanicity: General and Foster Care Population

URBANICITY (County-Level)	General Population (%)	Foster Care Population (%)
Metropolitan	8.4	10.4
Non-Metropolitan	7.8	10.0
Rural	7.7	12.9

Table 4. Use of Higher-than-Recommended Doses of Antipsychotics in Children and Adolescents by State

	General Population			Foster Care Population		
	%	Numerator	Denominator	%	Numerator	Denominator
Mean	7.9	1,256	15,185	9.2	315	3,040
AZ	6.7	626	9,357	8.5	107	1,253
CA	10.1	3,209	31,638	11.7	1,064	9,071
GA	7.6	1,083	14,337	9.7	341	3,510
IN	7.0	1,219	17,445	8.8	225	2,561
KS	8.7	657	7,514	9.5	241	2,534
KY	10.6	1,338	12,680	11.0	239	2,171
MI	6.7	1,387	20,744	9.6	401	4,156
MO	7.6	1,231	16,126	11.3	481	4,274
NM	8.1	297	3,685	7.8	31	395
NY	8.5	2,669	31,496			
RI	5.1	103	2,012	4.2	20	471
Min	5.1	103	2,012	4.2	20	395
Median	7.6	1,219	14,337	9.6	240	2,548
Max	10.6	3,209	31,638	11.7	1,064	9,071

Data source: MAX 2008

Table 5. Use of Higher-than-Recommended Doses of Antipsychotics in Children and Adolescents by Health Plan: General Population

	%	Numerator	Denominator
Mean	5.7	63	1,125
Plan 1	5.6	72	1,279
Plan 2	4.4	66	1,512
Plan 3	11.7	134	1,142
Plan 4	5.8	84	1,448
Plan 5	4.9	172	3,541
Plan 6	4.9	69	1,416
Plan 7	4.6	23	495
Plan 8	5.4	124	2,289
Plan 9	8.3	62	751
Plan 10	2.7	10	370
Plan 11	5.7	24	422
Plan 12	4.7	72	1,520
Plan 13	3.3	32	978
Plan 14	5.4	23	429
Plan 15	5.7	56	985
Plan 16	4.0	7	177
Plan 17	9.6	35	365
Min	2.7	7	177
Median	5.4	62	985
Max	11.7	172	3,541

Data Source: NYS Medicaid Managed Care Plan Data, 2010